AquaBounty Technologies Past Earnings Performance
Past criteria checks 0/6
AquaBounty Technologies's earnings have been declining at an average annual rate of -16.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 57.7% per year.
Key information
-16.6%
Earnings growth rate
24.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 57.7% |
| Return on equity | -16.7% |
| Net Margin | -1,114.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
AquaBounty: Not Casting A Lure Yet
Aug 20AquaBounty Technologies GAAP EPS of -$0.08, revenue of $1.07M
Aug 09AquaBounty CEO Sylvia Wulf - Genetically Modified Sustainable Salmon
Mar 15AquaBounty Technologies' First Genetically Engineered Salmon On The Plate - Should You Join The Stream?
Jun 02Here's Why AquaBounty Technologies (NASDAQ:AQB) Can Manage Its Debt Despite Losing Money
May 09
AquaBounty Technologies: Teach A Man To Fish And You Will Feed Him For A Lifetime
May 03What Kind Of Shareholders Hold The Majority In AquaBounty Technologies, Inc.'s (NASDAQ:AQB) Shares?
Feb 10Aquabounty Technologies launches stock offering; stock down ~5% after hours
Feb 03Richard Huber Is The Independent Non-Executive Director of AquaBounty Technologies, Inc. (NASDAQ:AQB) And They Just Picked Up 16% More Shares
Dec 20AquaBounty Technologies proposes public offering
Dec 09Revenue & Expenses BreakdownBeta
How AquaBounty Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -28 | 14 | 1 |
| 30 Sep 23 | 2 | -25 | 12 | 1 |
| 30 Jun 23 | 2 | -25 | 12 | 1 |
| 31 Mar 23 | 3 | -24 | 12 | 1 |
| 31 Dec 22 | 3 | -22 | 11 | 1 |
| 30 Sep 22 | 3 | -22 | 11 | 1 |
| 30 Jun 22 | 3 | -24 | 11 | 2 |
| 31 Mar 22 | 2 | -23 | 11 | 2 |
| 31 Dec 21 | 1 | -22 | 10 | 2 |
| 30 Sep 21 | 1 | -22 | 10 | 2 |
| 30 Jun 21 | 0 | -19 | 9 | 2 |
| 31 Mar 21 | 0 | -17 | 8 | 2 |
| 31 Dec 20 | 0 | -16 | 7 | 2 |
| 30 Sep 20 | 0 | -14 | 7 | 2 |
| 30 Jun 20 | 0 | -13 | 7 | 2 |
| 31 Mar 20 | 0 | -14 | 8 | 2 |
| 31 Dec 19 | 0 | -13 | 7 | 2 |
| 30 Sep 19 | 0 | -14 | 4 | 3 |
| 30 Jun 19 | 0 | -14 | 5 | 3 |
| 31 Mar 19 | 0 | -13 | 4 | 3 |
| 31 Dec 18 | 0 | -12 | 4 | 3 |
| 30 Sep 18 | 0 | -11 | 7 | 4 |
| 30 Jun 18 | 0 | -10 | 7 | 4 |
| 31 Mar 18 | 0 | -10 | 6 | 4 |
| 31 Dec 17 | 0 | -9 | 5 | 3 |
| 30 Sep 17 | 0 | -9 | 6 | 3 |
| 30 Jun 17 | 0 | -9 | 5 | 3 |
| 31 Mar 17 | 0 | -9 | 5 | 3 |
| 31 Dec 16 | 0 | -8 | 5 | 3 |
| 30 Sep 16 | 0 | -8 | 4 | 4 |
| 30 Jun 16 | 0 | -7 | 3 | 4 |
| 31 Mar 16 | 0 | -7 | 4 | 4 |
| 31 Dec 15 | 0 | -7 | 4 | 3 |
| 30 Sep 15 | 0 | -7 | 4 | 3 |
| 30 Jun 15 | 0 | -7 | 5 | 3 |
| 31 Mar 15 | 0 | -7 | 5 | 3 |
| 31 Dec 14 | 0 | -7 | 4 | 3 |
| 30 Sep 14 | 0 | -7 | 5 | 2 |
| 30 Jun 14 | 0 | -6 | 4 | 2 |
| 31 Mar 14 | 0 | -5 | 3 | 2 |
| 31 Dec 13 | 0 | -5 | 3 | 2 |
| 30 Sep 13 | 0 | -4 | 3 | 2 |
Quality Earnings: AQB is currently unprofitable.
Growing Profit Margin: AQB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AQB is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare AQB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AQB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: AQB has a negative Return on Equity (-16.7%), as it is currently unprofitable.